NCT03327220已完成不适用
A Post-Market, Prospective, Randomized, Controlled Study To Evaluate The Iovera° Device In Treating Pain Associated With Total Knee Arthroplasty
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 124
- 试验地点
- 2
- 主要终点
- Cumulative Opioid Consumption
研究概览
简要总结
This study is designed to investigate whether iovera° treatment prior to TKA decreases cumulative participant opioid use over the course of 6 weeks following TKA while maintaining similar levels of pain relief. The study will also investigate whether there is a relationship between participants treated with iovera° and participant reported pain and function as measured by knee injury and osteoarthritis outcomes score (KOOS JR), numeric rating scale (NRS) for pain; use of hospital services post-TKA and improved physical rehabilitation as measured by range of motion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •22 to 79 years of age
- •Scheduled to undergo primary unilateral TKA under spinal anesthesia for primary diagnosis of osteoarthritis
- •Participant is a class I-III on the American Society of Anesthesiology (ASA) Physical Classification System
- •Anticipation of discharge to home after inpatient acute post-op phase based on age, co-morbidities, home environment, and social support are in favor of discharge to home in the opinion of the Investigator.
- •Participant is willing and able to give written informed consent.
- •Participant is fluent in verbal and written English.
- •Participant is willing and able to comply with study instructions and commit to all follow-up visits for the duration of the study.
- •Participant is in good general health and free of any systemic disease state or physical condition that might impair evaluation or which in the Investigator's opinion, exposes the participant to an unacceptable risk by study participation.
排除标准
- •Chronic opioid use (defined as daily or almost daily use of opioids for >3 months).
- •Concurrent painful physical condition, surgery, or musculoskeletal disease that requires analgesic treatment during study follow-up that is not strictly related to the target knee being treated with iovera°, which have the potential to confound the postoperative assessments (e.g., significant pain from other joints, chronic neuropathic pain, concurrent or planned contralateral TKA, concurrent foot, neck, spine, hip, or other musculoskeletal disease, arthritis, or planned surgery, etc.).
- •Greater than 15° malalignment (varus or valgus) on pre-operative radiograph.
- •Previous Myoscience treatment.
- •Previous Partial or Total Knee Arthroplasty. Partial or Total Knee Arthroplasty of the contralateral knee is permitted if surgery was completed at least nine (9) months prior to Screening.
- •Body Mass Index ≥ 40
- •Prior surgery in the treatment areas that may alter the anatomy of the infrapatellar branch of the saphenous nerve (ISN) or the anterior femoral cutaneous nerve (AFCN) or result in scar tissue in the treatment area.
- •Any clotting disorder and/or use of an anticoagulant (e.g. warfarin, clopidogrel, etc.) within seven (7) days prior to administration of the device. Low dose aspirin (81mg or less daily) for cardiac prophylaxis allowed.
- •Any local skin condition at the treatment sites that in the Investigator's opinion would adversely affect treatment or outcomes.
- •Open and/or infected wound in the treatment areas.
- •Allergy to lidocaine.
- •History of cryoglobulinemia
- •History of paroxysmal cold hemoglobinuria.
- •History of cold urticaria.
- •History of Raynaud's disease.
- •History of opioid or alcohol abuse.
- •Participant is pregnant or planning to become pregnant while enrolled in the study.
- •Current enrollment in any investigational drug or device study or participation within 30 days prior to screening.
- •Currently being treated for related knee injury under worker's compensation claim or equivalent (i.e. legal case).
- •Any chronic medical condition that in the Investigator's opinion would prevent adequate participation.
- •Any chronic medication use (prescription, over-the-counter, etc.) that in the Investigator's opinion would affect study participation or participant safety.
- •For any reason, in the opinion of the Investigator, the participant may not be a suitable candidate for study participation (i.e., history of noncompliance, drug dependency, etc.).
结局指标
主要结局
Cumulative Opioid Consumption
时间窗: From the time of TKA surgery to 6 weeks post-TKA surgery
The cumulative consumption of opioids was determined from the time of Total Knee Arthroplasty (TKA) surgery to 6 weeks post-TKA surgery. Opioid consumption was converted to morphine milligram equivalents (MME) and participant consumption was verified by pill count at follow-up visits. The cumulative morphine equivalent was divided by the number of days to provide the total daily morphine equivalent (TME) for the participant,
次要结局
- Area Under the Curve (AUC)/Time for Change From Baseline in Knee Injury and Osteoarthritis Outcomes Score (KOOS JR.) Overall Score Through 6 Weeks Post-TKA(Baseline to 6 weeks post-TKA surgery)
- AUC/Time for Change From Baseline in Numeric Rating Scale (NRS) for Pain Through 6 Weeks Post-TKA(Baseline to 6 weeks post-TKA surgery)
- AUC/Time for Change From Baseline in Timed Get Up and Go (TUG) Tests Through 6 Weeks Post-TKA(Baseline to 6 weeks post-TKA surgery)
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
Cara CDRM (Conduction Disturbance Risk Monitor) 2.0Transcatheter Aortic Valve ReplacementNCT05465655Cara Medical Ltd33
招募中
不适用
Effect of Short-term Compression Therapy After Thermal Ablation for Varicose VeinsVaricose VeinsNCT05840991The Fourth Affiliated Hospital of Zhejiang University School of Medicine360
招募中
4 期
Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic DiseasePneumonia, PneumocystisAutoimmune Inflammatory Rheumatic DiseaseAutoimmune DiseasesConnective Tissue DiseasePreventionNCT06499233Tongji Hospital800
Unknown
不适用
Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine SurgeryMetastatic DiseaseSpinal DegenerationSpinal DeformitySpinal Cord InjuryNCT03632005John Street550
已完成
3 期
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)Pancreatic NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsPancreatic DiseasesDigestive System DiseasesEndocrine System DiseasesGemcitabineAntimetabolites, AntineoplasticNCT01964430Celgene866